N‐acetylcysteine for schizophrenia: A systematic review and meta‐analysis
Abstract
Appendix S1. Supporting Information Figure S1. Literature search Figure S2. Forest plots Figure S3. Bubble plots Figure S4. Funnel plot Table S1. The results of previous meta-analyses Table S2. PRISMA checklist Table S3. Study characteristics Table S4. Risk of bias summary Table S5. Meta-regression analysis Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Systematic review and meta-analysis of NAC in schizophrenia patients found individuals in acute phase were most responsive to treatment with NAC than those not in acute phase; considerable heterogeneity across subgroups noted.
“A systematic review and meta-analysis of N-acetylcysteine in schizophrenia patients have been carried out (Kishi et al. 2023). Both subgroups, individuals in the acute phase and in the non-acute phase were supplied with N-acetylcysteine. Individuals with schizophrenia in the acute phase were most responsive to the treatment with N-acetylcysteine than those who were not in the acute phase. However,”
From Reactive Oxygen Species, Toxicity, Oxidative Stress, and Antioxidants: Chronic Diseases and Aging (2023) · cites this paper as Kishi et al. 2023
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283 · see citing works
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · see citing works
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378 · see citing works
Jeppesen, R., Christensen, R. H. B., Pedersen, E. M. J., Nordentoft, M., Hjorthøj, C., Köhler-Forsberg, O., & Benros, M. E. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.08.028 · Cited by 132 · see citing works
Yolland, C. O. B., Hanratty, D., Neill, E., Rossell, S. L., Berk, M., Dean, O. M., Castle, D. J., Tan, E. J., Phillipou, A., Harris, A. W. F., et al. (2019) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867419893439 · Cited by 112 · see citing works
Czekus, C., Steullet, P., López, A. O., Bozic, I., Rusterholz, T., Bandarabadi, M., Kim, Q., & Herrera, C. G. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01700-w · Cited by 17 · see citing works
Yolland, C., Hanratty, D., Neill, E., et al. (2020) · Figshare · doi:10.25916/sut.26252087 · Cited by 8 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Reactive Oxygen Species, Toxicity, Oxidative Stress, and Antioxidants: Chronic Diseases and Aging
Jomova, K., Raptova, R., Alomar, S. Y., Alwasel, S. H., Nepovimova, E., Kuca, K., & Valko, M. (2023) · Archives of Toxicology · doi:10.1007/s00204-023-03562-9 · Cited by 2,638 · see citing works
Lu, Z., Yang, Y., Zhao, G., Zhang, Y., Sun, Y., Liao, Y., Kang, Z., Feng, X., Sun, J., & Yue, W. (2024) · Antioxidants · doi:10.3390/antiox13040398 · Cited by 14 · see citing works
Drugs with glutamate-based mechanisms of action in psychiatry
Chrobak, A. A., & Siwek, M. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00656-8 · Cited by 14 · see citing works
Gee, A., Dazzan, P., Grace, A. A., & Modinos, G. (2025) · Translational Psychiatry · doi:10.1038/s41398-024-03221-2 · Cited by 12 · see citing works
Augmentation with glutamatergic modulators for schizophrenia: A network meta-analysis
Liang, C.-W., Cheng, H.-Y., & Tseng, M. M. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111495 · Cited by 3 · see citing works
Add-On Pharmacotherapy in Schizophrenia: Does It Improve Long-Term Outcomes? A Systematic Review
Smyrnis, A., Smyrnis, G., & Smyrnis, N. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14217847 · Cited by 2 · see citing works
Ghanem, Y., Almarshedi, A. A., Adam, M. A. A., Eid, M., Karaliūnienė, R., Philip, S., & Hayek, S. E. (2024) · Nutritional neurosciences · doi:10.1007/978-981-97-2681-3_12
Zhang, J., Shen, N., Wang, P., Qiu, J., Luo, Y., Ding, Y., Liu, C., Jin, Y., Zhao, N., Cong, G., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-8104089/v1
Esuaikoh, V., Ibegbulam, S., Cook, A. J., McFarland, B., Nunnington, N., Perera, A., Feng, J., Cale, J. A., & King, M. V. (2026) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2026.1784522
Rogóż, Z., & Wąsik, A. (2026) · Pharmacological Reports · doi:10.1007/s43440-026-00853-7
Gilbert, D. L., Aschbacher‐Smith, L., Migneault, K. Y., Huddleston, D. A., Cecil, K. M., Beebe, D. W., Zhang, B., Ratner, N., & Prada, C. E. (2026) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2026.04.024
Schizophrenia: Converging Neurobiological Mechanisms and Emerging Therapeutic Strategies
Gong, C.-M., Liu, K.-Z., Wang, P., Wen, M.-Y., Wang, J., Li, Z.-Y., Lu, W.-J., Wang, Z.-L., Lu, L.-F., & Feng, R. (2026) · Biomolecules · doi:10.3390/biom16091283
Repurposing landscape of N-acetylcysteine: A scoping review of reviews toward clinical translation
Alaili, M. K. A. (2026) · PLoS ONE · doi:10.1371/journal.pone.0360434
- Authors
- Kishi, T., Sakuma, K., Hatano, M., & Iwata, N.
- Affiliations
- Fujita Health University (JP)
- Corresponding author
- Kishi, Taro
- Venue
- Psychiatry and Clinical Neurosciences
- Publisher
- Wiley
- Published
- 2022-11-19
- Volume
- 77
- Issue
- 2
- Pages
- 119-121
- ISSN
- 1323-1316 (ISSN-L)
- 1440-1819
- OpenAlex
- W4308179453
- Cited by
- 13
- References
- 7
- Citations by year
- 2026: 6 · 2025: 3 · 2024: 3 · 2023: 1
- FWCI
- 0.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Psychiatry and Clinical Neurosciences (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Keywords
- N-acetylcysteine, schizophrenia, glutathione precursor, glutathione, antioxidant therapy, treatment efficacy
- MeSH terms
- Acetylcysteine, Humans, Schizophrenia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
